Mangaluru: Students protest after finding dead rats, cats in college well

Mangaluru, May 6: The Kanara Chamber of Commerce and Industry has urged the government to consider erstwhile undivided Dakshina Kannada (now DK & Udupi) as one unit for the purpose of movement of people. KCCI president Isaac Vas has written a letter to Karnataka chief secretary T M Vijay Bhaskar in this regard. 

Mr Vas said: Even though the erstwhile Dakshina Kannada district was bifurcated in 1997 for administration purposes, the two districts are actually an urban agglomeration with most of the population residing in suburbs/towns. Office Staff, technical crew and labour of many industries reside in either district and commute daily for work within an efficient transport system.

The present restriction on Inter-district movement in view of the Lockdown is hindering the kick starting of industries and commerce. Workers are deprived of their livelihood and Industry and business owners are finding it challenging to move forward. To add to this, the migrant labour is moving back to their native places further aggravating the situation. Many Industries and Commercial establishments have requested us to take up this matter with the government, he said.

“Hence, we kindly request you to consider these two districts as one geographical area for the movement of people and private vehicles,” he said adding that this would facilitate movement of people for employment and business in either districts of Dakshina Kannada & Udupi.

He pointed out that Bangalore Rural, Bangalore Urban, Ramanagara, Chikkaballapur and Kolar are considered as a single unit as per your order No. RD158/TNR 2020 dt 03/05/2020 (Clause 2(a)).

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.